NCT00292864View on ClinicalTrials.gov

Safety Assessment of One-hour Infusions of SNS-032 for the Treatment of Select Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

January 31, 2006

Study Completion Date

December 31, 2007

Conditions
Tumors
Interventions
DRUG

SNS-032 Injection

Trial Locations (6)

19111

Fox Chase Cancer Center, Philadelphia

85260

Premiere Oncology of Arizona, Scottsdale

95817

University of California Davis Medical Center, Davis

02115

Dana-Farber Cancer Institute, Boston

02215

Beth Israel Deaconess Medical Center, Boston

Massachusetts General Hospital, Boston

Sponsors
All Listed Sponsors
lead

Sunesis Pharmaceuticals

INDUSTRY